amikacin has been researched along with Neonatal Sepsis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Da Costa, RMA; Darlow, CA; Das, S; Ellis, S; Farrington, N; Franceschi, F; Hope, W; Jagota, B; Jimenez-Valverde, A; Johnson, A; Kolamunnage-Dona, R; McEntee, L; Neely, M; Piddock, L; Sharland, M; Unsworth, J | 1 |
| Ceballos, J; Cortínez, L; García, A; Ibacache, M; Inojosa, R; Leguizamon, L; Maccioni, A; Meza, S; Paredes, N; Paulos, C; Ramírez, M; Severino, N; Toso, A; Urzúa, S; Von Mentlen, C | 1 |
| Acman, M; Chiu, CH; Hamawandi, A; Lindsay, JA; Readman, JB; Sharland, M; Standing, JF | 1 |
| Barros, M; Cunha, MS; Garrido, R; Tavares, A | 1 |
| Greisen, G; Gupta, M; Jakobsen, JC; Korang, SK; Lausten-Thomsen, U; Nava, C; Safi, S | 1 |
| Kelly, LE; Murthy, P; Shah, PS; Shivananda, S; Srinivasjois, R | 1 |
2 review(s) available for amikacin and Neonatal Sepsis
| Article | Year |
|---|---|
Antibiotic regimens for late-onset neonatal sepsis.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; Aztreonam; Bias; Cefazolin; Clavulanic Acid; Drug Therapy, Combination; Floxacillin; Gentamicins; Humans; Infant, Newborn; Neonatal Sepsis; Randomized Controlled Trials as Topic; Ticarcillin; Vancomycin | 2021 |
Antibiotics for neonates born through meconium-stained amniotic fluid.
Topics: Amikacin; Amniotic Fluid; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Gentamicins; Humans; Incidence; Infant, Newborn; Length of Stay; Meconium; Meconium Aspiration Syndrome; Neonatal Sepsis; Randomized Controlled Trials as Topic; Respiration, Artificial; Respiratory Insufficiency | 2017 |
4 other study(ies) available for amikacin and Neonatal Sepsis
| Article | Year |
|---|---|
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings.
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Delivery of Health Care; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Neonatal Sepsis | 2022 |
Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis.
Topics: Amikacin; Anti-Bacterial Agents; Humans; Infant, Newborn; Metabolic Clearance Rate; Neonatal Sepsis; Sepsis | 2023 |
Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Escherichia coli; Gentamicins; Humans; Infant, Newborn; Microbial Sensitivity Tests; Neonatal Sepsis; Prevalence; Sulbactam | 2023 |
Late-onset neonatal sepsis:
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Central Venous Catheters; Colistin; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Male; Neonatal Sepsis; Parenteral Nutrition; Placenta; Pregnancy; Risk Factors | 2019 |